New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 28, 2015
12:59 EDTMDCOFly Watch: Medicines Co., Alnylam rise ahead of cholesterol study presentation
Subscribe for More Information
10:13 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADP (ADP) upgraded to Outperform from Market Perform at William Blair... ASML (ASML) upgraded to Buy from Hold at Berenberg... Abercrombie & Fitch (ANF) upgraded on Hollister fundamentals at RBC Capital... Akamai (AKAM) upgraded to Outperform from Market Perform at JMP Securities... Ares Capital (ARCC) upgraded to Outperform from Market Perform at Raymond James... Banco Santander (SAN) upgraded on valuation at Deutsche Bank... CIBC (CM) upgraded to Neutral from Underperform at Credit Suisse... Canon (CAJ) upgraded to Hold from Sell at Deutsche Bank... Citi (C) upgraded to Buy from Neutral at Guggenheim... Ctrip.com (CTRP) upgraded to Buy from Hold at Stifel... El Pollo Loco (LOCO) upgraded at Stifel... Genomic Health (GHDX) upgraded to Market Perform from Underperform at Raymond James... Golar LNG (GLNG) upgraded on valuation, upcoming project completion at Stifel... Habit Restaurants (HABT) upgraded to Buy from Hold at Stifel... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Himax (HIMX) upgraded to Outperform from Neutral at Credit Suisse... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Guggenheim... InterContinental (IHG) upgraded to Outperform from Neutral at Credit Suisse... Knight Transportation (KNX) upgraded to Strong Buy on valuation at Raymond James... LogMeln (LOGM) upgraded to Overweight from Sector Weight at Pacific Crest... Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Jaffray... Qunar (QUNR) upgraded on valuation, positive catalysts at Stifel... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ryder (R) upgraded to Strong Buy from Outperform at Raymond James... SVB Financial (SIVB) upgraded to Buy from Neutral at DA Davidson... Seagate (STX) upgraded to Buy from Hold at Cross Research... Sinopec (SNP) upgraded to Neutral from Sell at Citi... Summit Hotel Properties (INN) upgraded to Outperform at Baird... Texas Capital (TCBI) upgraded to Buy from Neutral at DA Davidson... The Medicines Co. (MDCO) upgraded to Buy from Hold at Jefferies... U.S. Bancorp (USB) upgraded to Buy from Neutral at Guggenheim... Weatherford (WFT) upgraded to Overweight from Equal Weight at Stephens.
09:31 EDTPRGOMylan vote not surprising, Perrigo likely to rise in near-term, says BMO Capital
BMO Capital analyst David Maris believes that Mylan (MYL) shareholders' vote in favor of Mylan's proposed takeover of Perrigo (PRGO) and authorizing the company to issue shares was the outcome expected by most investors and will not come as a surprise to the market. Maris noted that he expects Perrigo shares will rise in the coming days amid speculation on its next move and thinks the Mylan bid significantly undervalues the company, which he estimates is worth $246 per share on a stand-alone basis. The firm keeps an Outperform rating on Perrigo and a Market Perform rating on Mylan.
08:06 EDTPRGOPerrigo 'confident' shareholders will reject Mylan 's offer
Subscribe for More Information
07:22 EDTPRGOMylan shareholders approve proposed acquisition of Perrigo
Subscribe for More Information
06:35 EDTMDCOThe Medicines Co. upgraded to Buy from Hold at Jefferies
Jefferies upgraded The Medicines Co. to Buy and increased its price target to $43 from $29. The firm said company has multiple data readouts for pipeline assets over the next 12-18 months starting with PI data from ALN-PCSsc in patients with elevated LDL on Sunday morning. Jefferies also highlighted the ongoing TANGO 1 trial comparing Carbavance to piperacillin-tazobactam in 850 patients with complicated urinary tract infection with data expected in mid-2016 that should also support its thesis.
August 27, 2015
19:14 EDTCVSExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
10:06 EDTBAXHigh option volume stocks
High option volume stocks: GLOG ACI NGD BEAT BAX TTPH STJ FNF SSTK
08:32 EDTCVSCVS Health enters into two new clinical affiliations
CVS Health has entered into new clinical affiliations with two health systems, St. Luke's University Health Network in Bethlehem, Pennsylvania and TriHealth in Cincinnati, Ohio. Through these clinical affiliations, CVS Health will provide prescription and visit information to the participating health care organizations.
August 26, 2015
08:32 EDTCVSCVS Health to partner with telehealth providers to improve patient care
Subscribe for More Information
07:09 EDTIDRAVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
06:55 EDTPRGOMylan shares may sell off on affirmative Perrigo deal vote, says BMO Capital
With Mylan (MYL) set to hold a shareholder vote on August 28 regarding its proposed acquisition of Perrigo (PRGO), BMO Capital analyst David Maris predicts that if the vote goes in Mylan's favor, he expects Perrigo shares to rise and Mylan shares to fall. Afterward, he feels added overhangs, such as Teva's (TEVA) and Abbott's (ABT) shareholdings and potential short-term selling by arbitrageurs, will come into play, further pressuring Mylan shares.
05:58 EDTPRGOPerrigo CEO says company is 'very active in M&A,' Bloomberg reports
Subscribe for More Information
August 25, 2015
16:01 EDTCVSTarget sees $550M pretax gain after closing CVS transaction
Subscribe for More Information
13:22 EDTPRGOMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTPRGOTeva to refrain from voting at Mylan special meeting
Subscribe for More Information
10:21 EDTCAHCardinal Health to acquire majority stake in naviHealth
Cardinal Health announced that it is acquiring a majority stake in naviHealth and expects the transaction to close later this week. Privately-held naviHealth partners with health plans, health systems and providers to manage the post-acute segment of the care continuum. naviHealth's principal investor, Welsh, Carson, Anderson & Stowe, along with management, will continue to have an ownership interest in the business. Cardinal Health said it is acquiring 71% of naviHealth for approximately $290M, with a goal of acquiring the entire business within four years, in accordance with a series of call/put rights during that period of time. Cardinal expects this acquisition to be neutral to its FY16 non-GAAP diluted earnings per share from continuing operations as it is a partial period, and slightly accretive to non-GAAP diluted earnings per share from continuing operations beginning in FY17, the first full year post close. "From a GAAP perspective, it is too early in the process to provide any specific guidance on the amortization of intangible assets. Once the fair value estimates are complete, we will provide additional details. Recall that our FY16 assumptions provided on our earnings call on July 30, 2015 only included those acquisitions that had been completed through June 30," the company stated in an FAQ document related to the deal.
09:26 EDTCAH, CYHRBC Capital to hold a bus tour
Healthcare Bus Tour travels throughout Nashville, TN to visit with various healthcare companies on August 25-26.
August 24, 2015
11:43 EDTMDCOThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use